Evidence map›Paper›PMID 31342143›Full record

ArticleArchives of dermatological research2019

STAT3 polymorphisms and IL-6 polymorphism are associated with the risk of basal cell carcinoma in patients from northern Poland.

Martyna Sławińska, Monika Zabłotna, Jolanta Gleń, Joanna Lakomy, Roman J Nowicki, Michał Sobjanek

Open access · hybridAbstract read
In one paragraph

Article in Archives of dermatological research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Mastocytosis and Skin Cancer: The Current State of Knowledge.International journal of molecular sciences · 2023
    Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Martyna SławińskaDepartment of Dermatology, Venereology and Allergology, Medical University of Gdańsk, Smoluchowskiego 17 Street, 80-214, Gdańsk, Poland. mslawinska@gumed.edu.pl.ORCID http://orcid.org/0000-0001-8947-5675
Monika ZabłotnaDepartment of Dermatology, Venereology and Allergology, Medical University of Gdańsk, Smoluchowskiego 17 Street, 80-214, Gdańsk, Poland.
Jolanta GleńDepartment of Dermatology, Venereology and Allergology, Medical University of Gdańsk, Smoluchowskiego 17 Street, 80-214, Gdańsk, Poland.
Joanna LakomyDepartment of Patomorphology, Medical University of Gdańsk, Smoluchowskiego 17 Street, 80-214, Gdańsk, Poland.
Roman J NowickiDepartment of Dermatology, Venereology and Allergology, Medical University of Gdańsk, Smoluchowskiego 17 Street, 80-214, Gdańsk, Poland.
Michał SobjanekDepartment of Dermatology, Venereology and Allergology, Medical University of Gdańsk, Smoluchowskiego 17 Street, 80-214, Gdańsk, Poland.
Gdańsk Medical University · PL

Funding

The study was funded by the Medical University of Gdańsk Project No. 02-0066/07/253
6 · The paper itself

Abstract

Basal cell carcinoma (BCC) environment consists of stromal and inflammatory cells which produce variety of cytokines, chemokines and growth factors that may affect tumor behavior. One of the cytokines suggested to be involved in the pathogenesis of BCC is IL-6, which is the upstream element of IL-6/JAK/STAT3 pathway. The correlation between polymorphisms of the genes related to this pathway and cancer risk/prognosis have been previously investigated in several neoplasia, but available data concerning BCC are scarce. In the present study, rs1800795 (-174 G/C) IL-6 gene polymorphism and two polymorphisms in the STAT3 gene, namely rs2293152 (intron 11, C/G) and rs4796793 (-1697, C/G) were assessed in relation to the BCC risk and clinical course. Additionally, IL-6 serum level was assessed in relation to IL-6 genotype and clinical variables. The study included 254 unrelated patients with BCC and of mean age 70.39 ± 11.43 (69.83 ± 12.32 women, 71.03 ± 10.31 men) and 198 healthy, unrelated age- and sex-matched volunteers. IL-6 and STAT3 polymorphisms were analyzed using polymerase chain reaction with sequence-specific primers (SSP-PCR). Serum concentration of IL-6 was measured using the ELISA test. We have found that the presence of C allele in rs1800795 IL-6 gene polymorphism was associated with increased risk of BCC (aOR 1.86; 95% CI 1.22-2.84; p = 0.004). The presence of CC genotype in STAT3 rs2293152 polymorphism was associated with increased BCC risk in recessive model analysis (aOR 3.94; 95% CI 1.59-9.77; p = 0.003). In contrast, the presence of GC genotype in overdominant model was associated with decreased risk of BCC (aOR = 0.24; 95% CI 0.12-0.49; p < 0.0001). The presence of C allele in STAT3 rs2293152 polymorphism was associated with increased risk of BCC (aOR 1.31; 95% CI 1.01-1.69; p = 0.04). The presence of GG genotype in STAT3 rs4796793 polymorphism was associated with increased BCC risk in recessive model analysis (aOR 3.66; 95% CI 1.33-10.10; p = 0.012). The presence of G allele in STAT3 rs4796793 polymorphism was associated with increased risk of BCC (aOR 1.59; 95% CI 1.01-2.49; p = 0.04). IL-6 serum level positively correlated with the tumor size.

Indexed as

Genetic Predisposition to DiseaseAgedAged, 80 and overAllelesBasal Cell CarcinomaCase-Control StudiesFemaleHealthy VolunteersHumansInterleukin-6MaleMiddle AgedPolandPolymorphism, Single NucleotideSkinSkin NeoplasmsIL6 protein, humanInterleukin-6STAT3 protein, humanSTAT3 Transcription FactorBasal cell carcinomaBCCGene polymorphismInterleukin-6Signal transducer and activator of transcription 3STAT3

Identifiers

PMID31342143
PMCPMC6787107
OpenAlexW2964344736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.